← All drugs Report issue

jnj-87801493

mAbexperimentalTri-specific

Clinical trial activity

1 trials · 0 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

0

Phase 3

0

Phase 4

0

Earliest trial started Dec 6, 2023 (NCT06139406)

Timeline

No events for the selected filters.

Indications

Studied for

Lymphoma, Non-Hodgkin · Phase 1

Mechanism of action

T-cell surface glycoprotein CD3 epsilon chainACTIVATOR
CD3E activator
- T-cell surface glycoprotein CD3 epsilon chain (CD3E) ↗
B-cell antigen receptor complex-associated protein beta chainBINDING AGENT
CD79B binding agent
- B-cell antigen receptor complex-associated protein beta chain (CD79B) ↗
B-lymphocyte antigen CD20BINDING AGENT
MS4A1 binding agent
- B-lymphocyte antigen CD20 (MS4A1) ↗

Chemistry & pharmacology

Multi-specific: Yes (Tri-specific)

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06139406	Phase 1	Dec 6, 2023	—

Showing 1 of 1 trials

Page 1 / 1